In response to the Office Action of September 29, 2003, please amend the application as follows:

IN THE CLAIMS

Please cancel claims 1-26, inclusive, without prejudice or disclaimer. Please add new claims 27-51, as follows:

27. (New) An isolated composition consisting essentially of immunoglobulins, as the active ingredient, and a polysaccharide selected from the group consisting of chitosanes and alginates, wherein the molecules of polysaccharide are neither chemically cross-linked to the immunoglobulins, nor to each other.

28. (New) The composition according to claim 27, wherein the immunoglobulins and the polysaccharides are associated by means of non-covalent links.

29. (New) The composition according to claim 27, wherein the chitosanes are selected from the group consisting of chitosanes with a low molecular weight and a high degree of deacetylation, methylglycolchitosane, and salts thereof.

30. (New) The composition according to claim 29, wherein the chitosane is metilglicolchitosane or its salts.

31. (New) The composition according to claim 27, wherein the alginates are selected from the group consisting of polymannuronic acid, alginic acid and its enzymatic fragments, and salts thereof.

32. (New) The composition according to claim 27, wherein said immunoglobulins are selected from the group consisting of IgG, IgA, or their fragments $F(ab')_2$ or F(ab) or scFv.

33. (New) The composition according to claim 32, wherein said immunoglobulins are IgG or their fragments $F(ab')_2$ or F(ab) or scFv.

34. (New) The composition according to claim 27, wherein said immunoglobulins are specific for substances selected from the group consisting of toxins, infectious agents, hormones, enzymes, proenzymes, drugs of abuse, medicines, bioactive peptides, metabolites, physiologic precursors and their antigenic components.

35. (New) The composition according to claim 34, wherein said toxins are of

mycotic origin.

36. (New) The composition according to claim 35, wherein said toxins are selected from the group consisting of ochratoxin, aflatoxin, zearalonon and fumonisine.

37. (New) The composition according to claim 34, wherein the infectious agents are selected from the group consisting of Herpes simplex virus, cytomegalovirus (CMV), chickenpox virus, rubella virus, syncytial virus, respiratory virus, influenza virus, Epstein-Barr virus, Listeria monocytogenes, Salmonella thipy, Salmonella entheriditis, Salmonella paratiphy, Salmonella thiphymurium, Salmonella choleraensis, Clostridium tetani, Clostridium botulinum or Shigella, Candida albicans, and Toxoplasma gondii.

38. (New) The compositions according to claim 37, further comprising immunomodulators isolated from Corynebacterium granulosum.

39. (New) The compositions according to claim 38, wherein said immunomodulator is the delipidated fraction of Corynebacterium granulosum.

40. (New) The composition according to claim 34, wherein said drugs of abuse are selected from the group consisting of cocaine, heroin, lysergic acid or their derivatives.

41. (New) The composition according to claim 34, wherein said medicines are selected from the group consisting of monensin, corticosteroids, antibiotics, anticoccidiostatics, antivirus, fungicides, chemiotherapic agents and sympathomimetic agents.

42. (New) The composition according to claim 34, wherein said substances are selected from the following groups:

- a) somatostatin, glucagon cholecystoquinine and growth hormone;
- b) parathormone and calcitonin;
- c) pentagastrin;
- d) thyroid hormone; and
- e) prothrombin.

43. (New) A therapeutic method for the treatment of growth-related problems, which comprises administering to a patient in need thereof the composition according to claim 42.

44. (New) A therapeutic method for the treatment of syndromes caused by an overdose of drugs of abuse, which comprises administering to a patient in need thereof the composition according to claim 42.

45. (New) A therapeutic method for the treatment of osteoporosis which comprises administering to a patient in need thereof the composition according to claim 42.

46. (New) A therapeutic method for the treatment of ulcer, which comprises administering a patient in need thereof the composition according to claim 42.

47. (New) The composition according to claim 37, for the preparation of food additives.

48. (New) The composition according to claim 27 for oral and transmucosal administration.

49. (New) The composition according to claim 48, wherein said transmucosal administration is perlingual, rectal, vaginal, or buccal.

50. (New) A process for the preparation of the composition according to claim 27 which comprises:

a) heating a solution of immunoglobulins in Na_2SO_4 wherein the immunoglobulins are present in a concentration from 5 to 50 mg/ml to a temperature from 50 to 60°C;

b) adding a solution containing a polysaccharides in a concentration from 0.1 to 10% by weight/volume; and

c) mixing by mechanical agitation.

51. (New) A process according to claim 50 wherein said polysaccharides are selected from the group consisting of alginic acid, polymannuronic acid, methylglycolchitosane, and chitosane with low molecular weight and high degree of deacetylation.